Objectives: To investigate the proportion of Chinese patients with intractable seizures and the risk factors leading to refractory epilepsy.
Methods: Consecutive patients over 14 years of age attending a Neurology clinic were evaluated. Patients with epilepsy were classified into two groups according to their seizure control: refractory or seizure-free. Epilepsy was classified as idiopathic as defined by age-related onset and typical electroclinical characteristics, symptomatic if secondary to a structural abnormality and cryptogenic if the cause was unknown. Age, sex, epilepsy syndrome classification, aetiology, presence of mental retardation and the number of drugs used were compared between patients with refractory epilepsy and those in remission.
Results: Among 260 adolescent and adult patients with a mean age of 34 years (range 15-79), complete seizure control was achieved in 157 (60%) cases. Multivariate binomial logistic regression analysis showed that patients with mesial temporal sclerosis (OR=7.6, 95% CI 3.53-16.4, p<0.01) and the presence of mental retardation (OR=9.39, 95% CI 3.98-22.12, p<0.01) were more likely to develop pharmacoresistant epilepsy.
Conclusion: In adults the underlying aetiology is an important factor as to whether patients develop intractable seizures. Poor control was also associated with the presence of mesial temporal sclerosis and mental retardation.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.clineuro.2007.05.016 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Seizure network characterization by functional connectivity mapping and manipulation.
Neurophotonics
January 2025
Weill Cornell Medicine, Department of Neurological Surgery, New York, United States.
Significance: Despite the availability of various anti-seizure medications, nearly 1/3 of epilepsy patients experience drug-resistant seizures. These patients are left with invasive surgical options that do not guarantee seizure remission. The development of novel treatment options depends on elucidating the complex biology of seizures and brain networks.
View Article and Find Full Text PDFIn vivo 9.4 Tesla MRI of a patient with drug-resistant epilepsy: Technical report.
Acta Neurochir (Wien)
January 2025
Department of Neurosurgery, Maastricht University Medical Centre, Maastricht, Netherlands.
Purpose: In resective epilepsy surgery for drug-resistant focal epilepsy (DRE), good seizure outcome is strongly associated with visualization of an epileptogenic lesion on MRI. Standard clinical MRI (≤ 3 Tesla (T)) may fail to detect subtle lesions. 7T MRI enhances detection and delineation, the potential benefits of increasing field strength to 9.
View Article and Find Full Text PDFEpilepsy therapy beyond neurons: unveiling astrocytes as cellular targets.
Neural Regen Res
January 2025
Shanghai Fifth People's Hospital, School of Pharmacy, MOE Key Laboratory of Smart Drug Delivery, MOE Innovative Center for New Drug Development of Immune Inflammatory Diseases, Department of Neurology, Huashan Hospital, Fudan University, Shanghai, China.
Epilepsy is a leading cause of disability and mortality worldwide. However, despite the availability of more than 20 antiseizure medications, more than one-third of patients continue to experience seizures. Given the urgent need to explore new treatment strategies for epilepsy, recent research has highlighted the potential of targeting gliosis, metabolic disturbances, and neural circuit abnormalities as therapeutic strategies.
View Article and Find Full Text PDFBiofluid-Permeable and Erosion-Resistant Wireless Neural-Electronic Interfaces for Neurohomeostasis Modulation.
ACS Nano
January 2025
School of Chemistry and Chemical Engineering, Nanjing University of Science and Technology, Nanjing 210094, P. R. China.
Neural-electronic interfaces through delivering electroceuticals to lesions and modulating pathological endogenous electrical environments offer exciting opportunities to treat drug-refractory neurological disorders. Such an interface should ideally be compatible with the neural tissue and aggressive biofluid environment. Unfortunately, no interface specifically designed for the biofluid environments is available so far; instead, simply stacking an encapsulation layer on silicon-based substrates makes them susceptible to biofluid leakage, device malfunction, and foreign-body reactions.
View Article and Find Full Text PDFImpact of lifetime antiepileptic drug history on cenobamate efficacy in adults with focal epilepsy.
Seizure
December 2024
Epilepsy Center, Medical Center, University of Freiburg, Breisacher Str. 64, 79106 Freiburg im Breisgau, Germany.
Purpose: To evaluate the efficacy of cenobamate (CNB) in adults with focal epilepsy based on the number of previous lifetime antiseizure medications (ASMs).
Methods: Twenty patients receiving add-on treatment with CNB with <6 lifetime ASMs were retrospectively compared to 20 Patients with >10 ASMs and approximately the same age. Efficacy was assessed at 3, 6, and 12 months following CNB initiation.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!